Loading…
SXTP
60 Degrees Pharmaceuticals Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 83006G500
$1.03-2.83%Price as of Aug 29, 18:49 UTC · updated once a day, after the close
Key metrics
- Market cap
- $3.62M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$2.59
- ROE
- -332.85%
- Profit margin
- 0.00%
- Revenue growth
- -32.50%
- Beta
- 2.54
- 52-week high
- $8.62
- 52-week low
- $1.01
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.8% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $2.03 | $25.80 | $244.80 | |
| P/S | 15.6x | 5.3x | 15.6x | 46.5x |
| P/B | 2.4x | 1.5x | 2.4x | 2.4x |
| EPS | -$11.73 | -$74.17 | -$236.72 | |
| Profit margin | -1308.01% | -732.51% | -1308.01% | -1485.06% |
| ROE | -196.93% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RDGTRidgetech Inc. | $1.00 | — | 0.0x | — | -3.55% | $3.63M |
| GOVXGeoVax Labs, Inc. | $0.72 | — | 3.0x | — | -891.59% | $3.76M |
| VIVSVivoSim Labs, INC. | $0.29 | — | 0.2x | — | -343.10% | $3.82M |
| SPRCSciSparc Ltd. | $6.58 |
About the company
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
- 3
- Washington, United States
Company description provided by Yahoo Finance.